Study suggests new drugs have improved outcomes in lung cancer
For the most common type of lung cancer in the U.S., the mortality rate is falling faster than the number of new cases, according to a new study, data that suggest targeted therapies are having a sizable effect on patients’ survival.
As STAT’s Elizabeth Cooney reports, the rate of death from non-small cell lung cancer, which accounts for three-quarters of cancers originating in the lung, has dropped since 2013, which coincides with the approval of genetically targeted medicines. Two-year survival also improved over the same period.
Experts say the improvement is undoubtedly tied to targeted cancer therapy, but there’s some debate over just how closely. Rates of smoking have declined in recent decades, and the fields of radiation oncology and minimally invasive surgery have progressed.
Read more.
As STAT’s Elizabeth Cooney reports, the rate of death from non-small cell lung cancer, which accounts for three-quarters of cancers originating in the lung, has dropped since 2013, which coincides with the approval of genetically targeted medicines. Two-year survival also improved over the same period.
Experts say the improvement is undoubtedly tied to targeted cancer therapy, but there’s some debate over just how closely. Rates of smoking have declined in recent decades, and the fields of radiation oncology and minimally invasive surgery have progressed.
Read more.
.png)
No hay comentarios:
Publicar un comentario